A prototypical example, Imatinib, targets BCR-Abl, a constitutively active form of the Abl kinase that leads to chronic myeloid leukemia (CML), and is very successful in the treatment of this disease[4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.